We are now expecting to enroll the first patients – mostly children – in the trial with PTG-007 this autumn.

At PolTREG, we believe that T1D one day will be a preventable disease. 

The trial is an important  step in that direction. By detecting the disease in high-risk patients we can start treating the disease with PTG-007  before any symptoms occur. 

This will free patients of the life-long burden of having to take frequent insulin injections, and the serious long-term complications of the disease.

PolTREG isn’t developing PTG-007 just for T1D, but for a wide range of auto-immune diseases. Later this year, we expect to launch Phase 1/2 trials with PTG-007 for two types of Multiple Sclerosis (MS): relapsing-remitting MS, in primary-progressive MS.